Lifecore Biomedical Stock Total Asset

LFCR Stock

6.67 0.02 0.30%

Lifecore Biomedical fundamentals help investors to digest information that contributes to Lifecore Biomedical's financial success or failures. It also enables traders to predict the movement of Lifecore Stock. The fundamental analysis module provides a way to measure Lifecore Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lifecore Biomedical stock.

	Last Reported	Projected for Next Year
Total Assets	314.8 M	248.7 M
Intangibles To Total Assets	0.35	0.30

As of 03/20/2025, Total Assets is likely to drop to about 248.7 M. In addition to that, Intangibles To Total Assets is likely to drop to 0.30.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lifecore Biomedical Company Total Asset Analysis

Lifecore Biomedical's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current Lifecore Biomedical Total Asset

273.7 M

Most of Lifecore Biomedical's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lifecore Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Lifecore Total Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for Lifecore Biomedical is extremely important. It helps to project a fair market value of Lifecore Stock properly, considering its historical fundamentals such as Total Asset. Since Lifecore Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lifecore Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lifecore Biomedical's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Intangible Assets	Common Stock	Current Deferred Revenue	Short Term Investments	Good Will	Net Tangible Assets	Long Term Debt	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Property Plant Equipment
Total Assets		0.76	0.62	0.48	0.75	0.69	0.85	0.4	0.89	0.31	-0.66	-0.48	-0.66	0.69	0.24	0.21	0.25	0.04	0.26	-0.2	-0.08	0.15
Total Stockholder Equity	0.76		0.0	0.91	0.8	0.08	0.45	0.17	0.77	0.63	-0.42	-0.46	-0.64	0.89	0.72	-0.34	0.71	0.63	0.69	-0.61	-0.6	0.66
Net Debt	0.62	0.0		-0.28	0.16	0.94	0.84	0.56	0.46	-0.31	-0.41	-0.21	-0.24	0.02	-0.44	0.67	-0.41	-0.67	-0.38	0.31	0.6	-0.53
Retained Earnings	0.48	0.91	-0.28		0.6	-0.27	0.22	0.11	0.52	0.72	-0.09	-0.38	-0.46	0.87	0.9	-0.55	0.87	0.83	0.86	-0.82	-0.75	0.83
Accounts Payable	0.75	0.8	0.16	0.6		0.32	0.48	0.2	0.89	0.53	-0.5	-0.46	-0.54	0.71	0.4	-0.33	0.48	0.48	0.57	-0.28	-0.56	0.58
Total Liab	0.69	0.08	0.94	-0.27	0.32		0.78	0.38	0.53	-0.22	-0.57	-0.25	-0.3	0.09	-0.43	0.69	-0.37	-0.62	-0.37	0.4	0.49	-0.48
Total Current Assets	0.85	0.45	0.84	0.22	0.48	0.78		0.69	0.76	0.16	-0.56	-0.47	-0.56	0.39	-0.02	0.35	-0.05	-0.29	0.03	-0.08	0.28	-0.15
Short Term Debt	0.4	0.17	0.56	0.11	0.2	0.38	0.69		0.44	-0.03	-0.2	-0.33	-0.31	0.05	-0.21	-0.03	-0.26	-0.19	-0.05	-0.13	0.29	-0.09
Net Receivables	0.89	0.77	0.46	0.52	0.89	0.53	0.76	0.44		0.34	-0.66	-0.53	-0.69	0.6	0.25	-0.14	0.27	0.19	0.41	-0.22	-0.25	0.32
Intangible Assets	0.31	0.63	-0.31	0.72	0.53	-0.22	0.16	-0.03	0.34		-0.19	-0.48	-0.43	0.68	0.71	-0.39	0.69	0.65	0.66	-0.59	-0.61	0.65
Common Stock	-0.66	-0.42	-0.41	-0.09	-0.5	-0.57	-0.56	-0.2	-0.66	-0.19		0.5	0.83	-0.16	0.17	-0.17	0.17	0.21	0.16	-0.13	-0.19	0.18
Current Deferred Revenue	-0.48	-0.46	-0.21	-0.38	-0.46	-0.25	-0.47	-0.33	-0.53	-0.48	0.5		0.57	-0.41	-0.24	0.18	-0.25	-0.19	-0.31	0.26	0.18	-0.25
Short Term Investments	-0.66	-0.64	-0.24	-0.46	-0.54	-0.3	-0.56	-0.31	-0.69	-0.43	0.83	0.57		-0.39	-0.18	0.13	-0.14	-0.13	-0.18	0.42	0.06	-0.14
Good Will	0.69	0.89	0.02	0.87	0.71	0.09	0.39	0.05	0.6	0.68	-0.16	-0.41	-0.39		0.81	-0.19	0.83	0.66	0.75	-0.63	-0.66	0.71
Net Tangible Assets	0.24	0.72	-0.44	0.9	0.4	-0.43	-0.02	-0.21	0.25	0.71	0.17	-0.24	-0.18	0.81		-0.49	0.97	0.85	0.91	-0.77	-0.81	0.84
Long Term Debt	0.21	-0.34	0.67	-0.55	-0.33	0.69	0.35	-0.03	-0.14	-0.39	-0.17	0.18	0.13	-0.19	-0.49		-0.47	-0.8	-0.65	0.53	0.73	-0.76
Net Invested Capital	0.25	0.71	-0.41	0.87	0.48	-0.37	-0.05	-0.26	0.27	0.69	0.17	-0.25	-0.14	0.83	0.97	-0.47		0.87	0.91	-0.72	-0.88	0.87
Long Term Investments	0.04	0.63	-0.67	0.83	0.48	-0.62	-0.29	-0.19	0.19	0.65	0.21	-0.19	-0.13	0.66	0.85	-0.8	0.87		0.88	-0.72	-0.96	0.97
Short Long Term Debt	0.26	0.69	-0.38	0.86	0.57	-0.37	0.03	-0.05	0.41	0.66	0.16	-0.31	-0.18	0.75	0.91	-0.65	0.91	0.88		-0.72	-0.9	0.94
Capital Stock	-0.2	-0.61	0.31	-0.82	-0.28	0.4	-0.08	-0.13	-0.22	-0.59	-0.13	0.26	0.42	-0.63	-0.77	0.53	-0.72	-0.72	-0.72		0.59	-0.71
Net Working Capital	-0.08	-0.6	0.6	-0.75	-0.56	0.49	0.28	0.29	-0.25	-0.61	-0.19	0.18	0.06	-0.66	-0.81	0.73	-0.88	-0.96	-0.9	0.59		-0.97
Property Plant Equipment	0.15	0.66	-0.53	0.83	0.58	-0.48	-0.15	-0.09	0.32	0.65	0.18	-0.25	-0.14	0.71	0.84	-0.76	0.87	0.97	0.94	-0.71	-0.97

Click cells to compare fundamentals

Lifecore Total Asset Historical Pattern

Today, most investors in Lifecore Biomedical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lifecore Biomedical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lifecore Biomedical total asset as a starting point in their analysis.

Lifecore Biomedical Total Asset

Timeline

Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

Competition

Predict Lifecore Biomedical

Total Assets Over Time

Lifecore Total Assets

Total Assets

248.67 Million

At this time, Lifecore Biomedical's Total Assets are relatively stable compared to the past year.

Based on the latest financial disclosure, Lifecore Biomedical has a Total Asset of 273.7 M. This is 96.36% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is 99.07% higher than that of the company.

Lifecore Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lifecore Biomedical's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lifecore Biomedical could also be used in its relative valuation, which is a method of valuing Lifecore Biomedical by comparing valuation metrics of similar companies.

Lifecore Biomedical is currently under evaluation in total asset category among its peers.

Lifecore Biomedical ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lifecore Biomedical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lifecore Biomedical's managers, analysts, and investors.

Environmental

Governance

Social

Lifecore Biomedical Institutional Holders

Institutional Holdings refers to the ownership stake in Lifecore Biomedical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lifecore Biomedical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lifecore Biomedical's value.

		Shares
State Street Corp	2024-12-31	375.3 K
Northern Trust Corp	2024-12-31	221.5 K
Tocqueville Asset Management L.p.	2024-12-31	151.7 K
Marshall Wace Asset Management Ltd	2024-12-31	133.2 K
Quinn Opportunity Partners Llc	2024-12-31	127.9 K
Alpha Wave Global Lp	2024-12-31	116.5 K
Ubs Group Ag	2024-12-31	109 K
Boothbay Fund Management, Llc	2024-12-31	87.1 K
Gamco Investors, Inc. Et Al	2024-12-31	86 K
Wynnefield Capital Inc	2024-12-31	4.7 M
Legion Partners Asset Management, Llc	2024-12-31	4.4 M

Lifecore Fundamentals

	Return On Equity	-0.3
	Return On Asset	-0.0247
	Profit Margin	(0.11) %
	Operating Margin	(0.05) %
	Current Valuation	365.14 M
	Shares Outstanding	37.03 M
	Shares Owned By Insiders	4.52 %
	Shares Owned By Institutions	73.59 %
	Number Of Shares Shorted	2.4 M
	Price To Book	15.75 X
	Price To Sales	1.88 X
	Revenue	128.26 M
	Gross Profit	45.64 M
	EBITDA	35.6 M
	Net Income	9.33 M
	Total Debt	130.36 M
	Book Value Per Share	0.42 X
	Cash Flow From Operations	(217 K)
	Short Ratio	19.93 X
	Earnings Per Share	(0.56) X
	Price To Earnings To Growth	3.51 X
	Target Price	10.0
	Number Of Employees	524
	Beta	0.97
	Market Capitalization	246.22 M
	Total Asset	273.7 M
	Retained Earnings	(166.52 M)
	Working Capital	42.16 M
	Net Asset	273.7 M

About Lifecore Biomedical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC